News & Updates

Show Multimedia Only
Dupilumab eases itch, disease activity in chronic spontaneous urticaria
Dupilumab eases itch, disease activity in chronic spontaneous urticaria
16 Jun 2025 byDr. Fernando Martinez, Weil Cornell Medical Center, New York City, New York, US; Dr. Richard Shek-Kwan Chang, Associate Consultant, Division of Neurology, Department of Medicine, Queen Mary Hospital, Hong Kong; รศ. พญ.ชุตินธร ศรีพระประแดง; Dr. Test John Doe, Doctor, Test University of Filipiñas, Ermita, España, Philippines; Dr. Margarita Sánchez del Rio, Clínica Universidad de Navarra, Madrid, Spain; Dr. Christina Man-Tung Cheung, Resident in Dermatology, Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong; Stephen Padilla

Patients with chronic spontaneous urticaria (CSA) who has uncontrolled disease despite treatment with H1-antihistamines may benefit from using dupilumab, which has been shown to reduce itch and urticaria activity in two phase III trials.

Dupilumab eases itch, disease activity in chronic spontaneous urticaria
16 Jun 2025
Lebrikizumab relieves itch, skin pain in AD patients previously on dupilumab
Lebrikizumab relieves itch, skin pain in AD patients previously on dupilumab
28 Mar 2025 byStephen Padilla

The use of lebrikizumab improves the symptoms of moderate-to-severe atopic dermatitis (AD) in patients previously treated with dupilumab, reports a study presented at AAD 2025.

Lebrikizumab relieves itch, skin pain in AD patients previously on dupilumab
28 Mar 2025
Eyebrow or eyelash hair loss affects QoL in AA patients
Eyebrow or eyelash hair loss affects QoL in AA patients
25 Mar 2025 byAudrey Abella

A real-world analysis presented at AAD 2025 shows that patients with alopecia areata (AA) with eyebrow or eyelash hair loss have greater health-related quality of life (HRQoL) burden than those without eyebrow and eyelash involvement.

Eyebrow or eyelash hair loss affects QoL in AA patients
25 Mar 2025